{"filing":{"accession_number":"0001193125-26-384363","cik":"0001422143","ticker":"KURA","company_name":"Kura Oncology, Inc.","form":"8-K","filing_date":"2026-09-08","report_date":"2026-09-08","primary_document":"d458603d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1422143/000119312526384363/d458603d8k.htm"},"events":[{"id":31769,"run_id":29169,"accession_number":"0001193125-26-384363","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The filing discloses the appointment of Jennifer Fulk as Chief Financial Officer, principal financial officer, and principal accounting officer of Kura Oncology, effective September 8, 2026. While the disclosure includes compensatory details (base salary of $550,000, bonus eligibility, equity awards of 450,000 options and 173,438 PSUs, and severance provisions), the principal action is the appointment of a named executive officer to a key financial leadership role. This is material to investors as CFO changes affect financial oversight and governance.","company_name":"Kura Oncology, Inc.","ticker":"KURA","filing_date":"2026-09-08","form":"8-K","submitted_at":null,"items":[{"id":34750,"accession_number":"0001193125-26-384363","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Jennifer Fulk as Chief Financial Officer, principal financial officer, and principal accounting officer of Kura Oncology, effective September 8, 2026. While the disclosure includes compensatory details (base salary of $550,000, bonus eligibility, equity awards of 450,000 options and 173,438 PSUs, and severance provisions), the principal action is the appointment of a named executive officer to a key financial leadership role. This is material to investors as CFO changes affect financial oversight and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T11:06:53.721612+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34750,"accession_number":"0001193125-26-384363","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Jennifer Fulk as Chief Financial Officer, principal financial officer, and principal accounting officer of Kura Oncology, effective September 8, 2026. While the disclosure includes compensatory details (base salary of $550,000, bonus eligibility, equity awards of 450,000 options and 173,438 PSUs, and severance provisions), the principal action is the appointment of a named executive officer to a key financial leadership role. This is material to investors as CFO changes affect financial oversight and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T11:06:53.721612+00:00","company_name":"Kura Oncology, Inc.","ticker":"KURA","filing_date":"2026-09-08"}]}